Filing Flows › Tonix Pharmaceuticals Holding (TNXP) › Q3 2026
Tonix Pharmaceuticals Holding (TNXP) Q3 2026 earnings results (third quarter 2026)
10-Q filed Nov 9, 2026
Tonix Pharmaceuticals Holding (TNXP) reported revenue of $17.2M for the third quarter 2026 (Q3 2026), +424% from a year earlier and +27% from the quarter before. Operating margin was -321.6%, net loss $53.3M (309.4% of revenue).
Tonix Pharmaceuticals Holding, Q3 2026: revenue $17.2M (+424% year over year), operating margin -321.6%, net loss $53.3M, operating cash flow −$41.1M. The chart follows the revenue to costs, profit and cash.
| Q3 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $17.2M | +27% | +424% |
| Operating profit | −$55.4M | — | — |
| Net earnings | −$53.3M | — | — |
| Operating cash flow | −$41.1M | — | — |
What changed
Revenue was $17.2M in Q3 2026, up 424% year over year and up 27% from the previous quarter. Tonmya was the largest line at 87% of revenue. Zembrace Symtouch declined 41%.
Operating costs exceeded revenue by $55.4M, an operating margin of -321.6%. Total costs grew 100% against revenue growth of 424%. The fastest-growing cost line was Research & development (+178%). The quarter ended with a net loss of $53.3M, wider than the previous quarter's $40.6M loss.
Operating cash flow was −$41.1M. Non-cash charges added back $643K of depreciation and amortization and $2.3M of share-based compensation. Working capital and other items added $9.3M. Capital expenditures of $603K exceeded it, leaving free cash flow of −$41.7M.
Questions
What was Tonix Pharmaceuticals Holding's revenue in the third quarter 2026?
Tonix Pharmaceuticals Holding (TNXP) reported revenue of $17.2M for the third quarter 2026 (Q3 2026), +424% from a year earlier and +27% from the quarter before.
Was Tonix Pharmaceuticals Holding profitable in the third quarter 2026?
Operating loss was $55.4M (-321.6% of revenue) and net loss $53.3M.